Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01478581 · OUTCOME

Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma · Source last updated 2020-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ng/mL
Interval / dispersion
Standard Deviation
Time frame
Procedure was performed up to 60 weeks.

What was measured

Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.

Analysis population: All subjects who received at least one dose of study treatment and had evaluable pharmacokinetic data.

Groups in this outcome

Cohort 1

PCI-32765 420 mg per day PCI-32765

Cohort 2

PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week PCI-32765 Dexamethasone

Cohort 3

PCI-32765 840 mg per day PCI-32765

Cohort 4

PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week PCI-32765 Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 113
Cohort 216
Cohort 318
Cohort 443

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Cohort 1157126Not reportedNot reportedNot reported
Cohort 210396.7Not reportedNot reportedNot reported
Cohort 3219159Not reportedNot reportedNot reported
Cohort 4166200Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        126
        value
        157
      2. group Id
        OG001
        spread
        96.7
        value
        103
      3. group Id
        OG002
        spread
        159
        value
        219
      4. group Id
        OG003
        spread
        200
        value
        166
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    2. group Id
      OG001
      value
      16
    3. group Id
      OG002
      value
      18
    4. group Id
      OG003
      value
      43
    units
    Participants
description
Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.
dispersion Type
Standard Deviation
groups
  1. description
    PCI-32765 420 mg per day PCI-32765
    id
    OG000
    title
    Cohort 1
  2. description
    PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week PCI-32765 Dexamethasone
    id
    OG001
    title
    Cohort 2
  3. description
    PCI-32765 840 mg per day PCI-32765
    id
    OG002
    title
    Cohort 3
  4. description
    PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week PCI-32765 Dexamethasone
    id
    OG003
    title
    Cohort 4
param Type
MEAN
population Description
All subjects who received at least one dose of study treatment and had evaluable pharmacokinetic data.
reporting Status
POSTED
time Frame
Procedure was performed up to 60 weeks.
title
Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice